{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:43:04Z","timestamp":1792190584864,"version":"4.4.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.tem.2021.10.009","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T08:22:04Z","timestamp":1639038124000},"page":"87-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["The changing clinical spectrum of endocrine adverse events in cancer immunotherapy"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-2392","authenticated-orcid":false,"given":"Sabrina","family":"Chiloiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Milardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2021.10.009_bb0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1172\/JCI131194","article-title":"Time to dissect the autoimmune etiology of cancer antibody immunotherapy","volume":"130","author":"Dougan","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2021.10.009_bb0010","doi-asserted-by":"crossref","first-page":"R116","DOI":"10.1530\/EC-20-0489","article-title":"Endocrine toxicity of cancer immunotherapy: clinical challenges","volume":"10","author":"Anderson","year":"2021","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.tem.2021.10.009_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101473","article-title":"Checkpoint blockade toxicities: insights into autoimmunity and treatment","volume":"52","author":"Walsh","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.tem.2021.10.009_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S110479","article-title":"First-line treatment of metastatic melanoma: role of nivolumab","volume":"6","author":"Force","year":"2017","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.tem.2021.10.009_bb0025","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.3390\/cancers12092497","article-title":"Neoadjuvant immune-checkpoint blockade in triple-negative breast cancer: current evidence and literature-based meta-analysis of randomized trials","volume":"12","author":"Marinelli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tem.2021.10.009_bb0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14737140.2018.1417845","article-title":"Current and future immunotherapies for thyroid cancer","volume":"18","author":"Antonelli","year":"2018","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.tem.2021.10.009_bb0035","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tem.2021.10.009_bb0040","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/35069112","article-title":"Structural basis for co-stimulation by the human CTLA-4\/B7-2 complex","volume":"410","author":"Schwartz","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.tem.2021.10.009_bb0045","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/35069118","article-title":"Crystal structure of the B7-1\/CTLA-4 complex that inhibits human immune responses","volume":"410","author":"Stamper","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.tem.2021.10.009_bb0050","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/cells9061376","article-title":"PD-1: its discovery, involvement in cancer immunotherapy, and beyond","volume":"9","author":"Ishida","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.tem.2021.10.009_bb0055","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.tem.2021.10.009_bb0060","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tem.2021.10.009_bb0065","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0070","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2021.10.009_bb0075","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0080","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tem.2021.10.009_bb0085","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1\u2013PD1 axis converts human T H1 cells into regulatory T cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0095","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","article-title":"B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.tem.2021.10.009_bb0100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari","year":"2018","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.tem.2021.10.009_bb0105","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.tem.2019.06.004","article-title":"The changing clinical spectrum of hypophysitis","volume":"30","author":"Chiloiro","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tem.2021.10.009_bb0110","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tem.2021.10.009_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101370","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2021.10.009_bb0120","doi-asserted-by":"crossref","first-page":"vii7","DOI":"10.1093\/rheumatology\/kez418","article-title":"Toxicities associated with checkpoint inhibitors \u2013 an overview","volume":"58","author":"Spiers","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.tem.2021.10.009_bb0125","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tem.2021.10.009_bb0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0135","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.trsl.2015.06.005","article-title":"Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma","volume":"166","author":"Quirk","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.tem.2021.10.009_bb0140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.tem.2021.10.009_bb0150","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.tem.2021.10.009_bb0155","doi-asserted-by":"crossref","first-page":"76565","DOI":"10.18632\/oncotarget.12088","article-title":"Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors","volume":"7","author":"Mei","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tem.2021.10.009_bb0160","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00262-021-02955-y","article-title":"Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome","volume":"70","author":"Kanie","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.tem.2021.10.009_bb0165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20022125","article-title":"The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0170","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.tem.2021.10.009_bb0175","doi-asserted-by":"crossref","first-page":"32318","DOI":"10.18632\/oncotarget.8698","article-title":"Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants","volume":"7","author":"Chowdhury","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tem.2021.10.009_bb0180","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/ERC-16-0421","article-title":"Comprehensive screening for PD-L1 expression in thyroid cancer","volume":"24","author":"Ahn","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2021.10.009_bb0185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/dbio.1994.1072","article-title":"Expression of magainin antimicrobial peptide genes in the developing granular glands of Xenopus skin and induction by thyroid hormone","volume":"162","author":"Reilly","year":"1994","journal-title":"Dev. Biol."},{"key":"10.1016\/j.tem.2021.10.009_bb0190","article-title":"Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review","volume":"7","author":"Schmerling","year":"2021","journal-title":"Fut. Sci. OA"},{"key":"10.1016\/j.tem.2021.10.009_bb0195","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1002\/cam4.2533","article-title":"Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma","volume":"8","author":"Kassi","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0200","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","article-title":"Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program","volume":"7","author":"Verzoni","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tem.2021.10.009_bb0205","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s11102-021-01141-8","article-title":"Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review","volume":"24","author":"Iglesias","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2021.10.009_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin. Diabetes Endocrinol."},{"key":"10.1016\/j.tem.2021.10.009_bb0215","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"De Filette","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.tem.2021.10.009_bb0220","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40618-019-01112-8","article-title":"Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study","volume":"43","author":"Presotto","year":"2020","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.tem.2021.10.009_bb0225","doi-asserted-by":"crossref","first-page":"E212","DOI":"10.7861\/clinmed.2020-0827","article-title":"Endocrine complications of immunotherapies: a review","volume":"21","author":"Hattersley","year":"2021","journal-title":"Clin. Med. (Lond)"},{"key":"10.1016\/j.tem.2021.10.009_bb0230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12902-019-0335-x","article-title":"Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report","volume":"19","author":"Takeno","year":"2019","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.tem.2021.10.009_bb0235","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/1346-8138.13486","article-title":"Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient","volume":"44","author":"Teramoto","year":"2017","journal-title":"J. Dermatol."},{"key":"10.1016\/j.tem.2021.10.009_bb0240","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.asjsur.2012.04.013","article-title":"IgG4-related hypophysitis presenting as a pituitary adenoma with systemic disease","volume":"36","author":"Hsing","year":"2013","journal-title":"Asian J. Surg."},{"key":"10.1016\/j.tem.2021.10.009_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2021.10.009_bb0250","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2021.10.009_bb0255","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2021.10.009_bb0260","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1002\/cam4.2661","article-title":"Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: a systematic review and meta-analysis","volume":"8","author":"Lu","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0265","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.tem.2021.10.009_bb0270","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/imj.12819","article-title":"Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series","volume":"45","author":"Lam","year":"2015","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.tem.2021.10.009_bb0275","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clineuro.2014.06.011","article-title":"Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis","volume":"125","author":"Chodakiewitz","year":"2014","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.tem.2021.10.009_bb0280","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2021.10.009_bb0285","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tem.2021.10.009_bb0290","article-title":"Hypophysitis, the growing spectrum of a rare pituitary disease","author":"Langlois","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2021.10.009_bb0295","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2021.10.009_bb0300","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.tem.2021.10.009_bb0305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.tem.2021.10.009_bb0310","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Bluestone","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.tem.2021.10.009_bb0315","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","article-title":"Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)","volume":"42","author":"Ruggeri","year":"2019","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.tem.2021.10.009_bb0320","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT","volume":"40","author":"Bacanovic","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0325","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan endocrine society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr. J."},{"key":"10.1016\/j.tem.2021.10.009_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.tem.2021.10.009_bb0335","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2021.10.009_bb0340","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/dme.13762","article-title":"Diabetes associated with immune checkpoint inhibition: presentation and management challenges","volume":"35","author":"Galligan","year":"2018","journal-title":"Diabet. Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0345","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.tem.2021.10.009_bb0350","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.tem.2021.10.009_bb0355","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.tem.2021.10.009_bb0360","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tem.2021.10.009_bb0365","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.tem.2021.10.009_bb0370","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a Malignant Melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.tem.2021.10.009_bb0375","first-page":"23","article-title":"Pembrolizumab-associated hypoparathyroidism: a single case report","volume":"7","author":"Mahmood","year":"2021","journal-title":"AACE Clin. Case Rep."},{"key":"10.1016\/j.tem.2021.10.009_bb0380","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2021.10.009_bb0385","doi-asserted-by":"crossref","first-page":"1039.e5","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100011","article-title":"How we treat endocrine complications of immune checkpoint inhibitors","volume":"6","author":"Paschou","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.tem.2021.10.009_bb0395","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13256-020-02502-w","article-title":"Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report","volume":"14","author":"Porntharukchareon","year":"2020","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.tem.2021.10.009_bb0400","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-231236","article-title":"Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency","volume":"12","author":"Martins Machado","year":"2019","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.tem.2021.10.009_bb0405","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7861\/clinmed.2020-0054","article-title":"Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus?","volume":"20","author":"Kyriacou","year":"2020","journal-title":"Clin. Med. (Lond)"},{"key":"10.1016\/j.tem.2021.10.009_bb0410","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejca.2020.01.013","article-title":"Impact of aging on immune-related adverse events generated by anti-programmed death (ligand) PD-(L)1 therapies","volume":"129","author":"Baldini","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tem.2021.10.009_bb0415","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000871","article-title":"Impact of age on the toxicity of immune checkpoint inhibition","volume":"8","author":"Samani","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tem.2021.10.009_bb0420","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejca.2018.04.005","article-title":"CTLA-4 gene variant \u22121661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab","volume":"97","author":"Queirolo","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tem.2021.10.009_bb0425","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/j.lpm.2018.10.019","article-title":"Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: retrospective study of 105 patients","volume":"48","author":"Campredon","year":"2019","journal-title":"Press. Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0430","first-page":"1225","article-title":"Potential risk factors for nivolumab-induced thyroid dysfunction","volume":"31","author":"Yamazaki","year":"2017","journal-title":"In Vivo (Brooklyn)"},{"key":"10.1016\/j.tem.2021.10.009_bb0435","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1530\/EJE-07-0649","article-title":"Association of an A\/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves\u2019 disease in Japanese patients","volume":"158","author":"Hayashi","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2021.10.009_bb0440","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/thy.2013.0170","article-title":"Autoimmune thyroid disease elicited by NY-ESO-1 vaccination","volume":"24","author":"Vita","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.tem.2021.10.009_bb0445","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa458","article-title":"Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index","volume":"105","author":"Pollack","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2021.10.009_bb0450","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tem.2021.10.009_bb0455","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2021.10.009_bb0460","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s40618-019-01058-x","article-title":"Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors","volume":"42","author":"Mazarico","year":"2019","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.tem.2021.10.009_bb0465","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study","volume":"8","author":"Kobayashi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tem.2021.10.009_bb0470","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.tem.2021.10.009_bb0475","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/cas.14363","article-title":"Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tem.2021.10.009_bb0480","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tem.2021.10.009_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102454","article-title":"Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors","volume":"19","author":"Percik","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.tem.2021.10.009_bb0490","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.2217\/fon-2019-0101","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"15","author":"Castillero","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.tem.2021.10.009_bb0495","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2147\/DDDT.S196316","article-title":"Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis","volume":"13","author":"Xu","year":"2019","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.tem.2021.10.009_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101411","article-title":"Checkpoint inhibitors and autoimmunity: why endocrinopathies and who is prone to?","volume":"34","author":"Percik","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2021.10.009_bb0505","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0510","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.4158\/ACCR-2019-0585","article-title":"A common pituitary autoantibody in two patients with immune checkpoint inhibitor-mediated hypophysitis: ZCCHC8","volume":"6","author":"Leiter","year":"2020","journal-title":"AACE Clin. Case Reports"},{"key":"10.1016\/j.tem.2021.10.009_bb0515","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tem.2021.10.009_bb0520","doi-asserted-by":"crossref","first-page":"R275","DOI":"10.1530\/EJE-17-0505","article-title":"Diagnosis of endocrine disease: primary empty sella: a comprehensive review","volume":"177","author":"Chiloiro","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2021.10.009_bb0525","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/jpm11101026","article-title":"Molecular and genetic immune biomarkers of primary and immune-therapy induced hypophysitis: from laboratories to the clinical practice","volume":"11","author":"Chiloiro","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.tem.2021.10.009_bb0530","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/EJE-17-0009","article-title":"Hypophysitis: diagnosis and treatment","volume":"179","author":"Joshi","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2021.10.009_bb0535","first-page":"1683","article-title":"MRI findings of immune checkpoint inhibitor-induced hypophysitis: possible association with fibrosis","volume":"41","author":"Kurokawa","year":"2020","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.tem.2021.10.009_bb0540","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.tem.2021.10.009_bb0545","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1210\/jc.2005-0860","article-title":"Extensive clinical experience: estimated risk for developing autoimmune Addison\u2019s disease in patients with adrenal cortex autoantibodies","volume":"91","author":"Coco","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2021.10.009_bb0550","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ando.2018.07.006","article-title":"Expert opinion on immunotherapy induced diabetes","volume":"79","author":"Smati","year":"2018","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"10.1016\/j.tem.2021.10.009_bb0555","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7861\/clinmed.2018-0440","article-title":"Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma","volume":"20","author":"Agarwal","year":"2020","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.tem.2021.10.009_bb0560","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00125-004-1626-x","article-title":"Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus","volume":"48","author":"Imagawa","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.tem.2021.10.009_bb0565","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-217454","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova","year":"2016","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.tem.2021.10.009_bb0570","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JOP.18.00076","article-title":"Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: a case report","volume":"14","author":"Umeguchi","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.tem.2021.10.009_bb0575","first-page":"20","article-title":"Pituitary metastasis unveiling a lung adenocarcinoma","volume":"2021","author":"Lopes","year":"2021","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"10.1016\/j.tem.2021.10.009_bb0580","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s40618-021-01508-5","article-title":"Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy","volume":"44","author":"Luongo","year":"2021","journal-title":"J. Endocrinol. Investig."}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276021002605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276021002605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:42:14Z","timestamp":1760906534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276021002605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1043276021002605"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2021.10.009","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The changing clinical spectrum of endocrine adverse events in cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2021.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}